{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cacciaglia R"],"funding":["European Research Council","NIA NIH HHS"],"pagination":["fcae451"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11668178"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(1)"],"pubmed_abstract":["CSF concentrations of β-amyloid 42 (Aβ42) and phosphorylated tau (p-tau) are well-established biomarkers of Alzheimer's disease and have been studied in relation to several neuropathological features both in patients and in cognitively unimpaired individuals. The CSF p-tau/Aβ42 ratio, a biomarker combining information from both pathophysiological processes, has emerged as a promising tool for monitoring disease progression, even at pre-clinical stages. Here, we studied the association between the CSF p-tau/Aβ42 ratio with downstream markers of pre-clinical Alzheimer's disease progression including brain structure, glucose metabolism, fibrillary Aβ deposition and cognitive performance in 234 cognitively unimpaired individuals, who underwent cognitive testing, a lumbar puncture, MRI, 18F-flu"],"journal":["Brain communications"],"pubmed_title":["The CSF p-tau/β-amyloid 42 ratio correlates with brain structure and fibrillary β-amyloid deposition in cognitively unimpaired individuals at the earliest stages of pre-clinical Alzheimer's disease."],"pmcid":["PMC11668178"],"funding_grant_id":["948677","R01 AG068398"],"pubmed_authors":["Canas A","Suarez-Calvet M","Gil CM","Gamez LI","Radoi IA","Rodriguez GH","Huguet J","Soteras A","Zetterberg H","Stankeviciute LS","Grau-Rivera O","Gispert JD","Falcon C","Fauria K","Hernandez L","Alvarez PM","Serra PG","Escalante AG","Ballester AP","Serrat AB","Molinuevo JL","Pascual M","Cacciaglia R","Penas LH","Shekari M","Iglesias RD","Aguilar RA","Pradas S","Ninou JH","Emilio M","Martinez AC","Quevenco FC","Gorriti AB","Palacios E","Cumplido I","Blennow K","Jaramillo MV","Mendez SP","Mahnaz MS","Fuentes S","Sanchez-Benavides G","Sanchez Benavides GA","Milan MD","Karine MEF","Gispert LC","ALFA Study","Freixedes LR","Rivera OG","Polo A","Calvet MS","Minguillon C","Diaz TM","Menchon T","Prat AS","Marne P","Salvado G","Vilanova M","Deulofeu C","Huesa G","Mila-Aloma M","Knezevic I","Gomez CD","Vila AS","Fernandez BR","Tejedor NV","Julian SF","Beteta A","Dominguez R","Harster LS"],"additional_accession":[]},"is_claimable":false,"name":"The CSF p-tau/β-amyloid 42 ratio correlates with brain structure and fibrillary β-amyloid deposition in cognitively unimpaired individuals at the earliest stages of pre-clinical Alzheimer's disease.","description":"CSF concentrations of β-amyloid 42 (Aβ42) and phosphorylated tau (p-tau) are well-established biomarkers of Alzheimer's disease and have been studied in relation to several neuropathological features both in patients and in cognitively unimpaired individuals. The CSF p-tau/Aβ42 ratio, a biomarker combining information from both pathophysiological processes, has emerged as a promising tool for monitoring disease progression, even at pre-clinical stages. Here, we studied the association between the CSF p-tau/Aβ42 ratio with downstream markers of pre-clinical Alzheimer's disease progression including brain structure, glucose metabolism, fibrillary Aβ deposition and cognitive performance in 234 cognitively unimpaired individuals, who underwent cognitive testing, a lumbar puncture, MRI, 18F-flu","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-03T04:57:11.285Z","creation":"2025-04-05T09:28:30.343Z"},"accession":"S-EPMC11668178","cross_references":{"pubmed":["39723106"],"doi":["10.1093/braincomms/fcae451"]}}